TransMedics Group is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across various disease states. Co. has developed the Organ Care System (OCS), a portable organ perfusion and monitoring system that using Co.'s technology to replicate near-physiologic conditions for donor organs outside of the human body. The OCS was designed to perfuse donor organs with warm, oxygenated and nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. Co.'s OCS products are one for each of lung, heart and liver transplantations. The TMDX stock yearly return is shown above.
The yearly return on the TMDX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TMDX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|